Full Length Research Paper
References
|
Akpaka PE, Vaillant A, Wilson C, Jayaratne P (2021). Extended Spectrum Beta-Lactamase (ESBL) Produced by Gram-Negative Bacteria in Trinidad and Tobago. International Journal of Microbiology 23:5582755. |
|
|
Alexandre K, Réveillon-Istin M, Fabre R, Delbos V, Etienne M, Pestel-Caron M, Dahyot S, Caron F (2018). Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: Low rate of resistance and good accuracy of routine susceptibility testing methods. Journal of Antimicrobial Chemotherapy 73(7):1848?1853. |
|
|
Alio MF, Laouali B, Ali M, Hadiza IB, Ali K, Chaibou Y, Cheikna Z, Chaibou S, Alhousseini D, Ramatou S (2017). Phenotypic detection of extended spectrum beta-lactamase in multidrug-resistant Escherichia coli from clinical isolates in Niamey, Niger. African Journal of Microbiology Research 11(18):712?717. |
|
|
Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B, Brudney D, Ladenheim D, Ghazy A, Khan I, Virgincar N, Iyer S, Carryn S, Van De Velde S (2011). Temocillin use in England?: Clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy 66(11):2628?2631. |
|
|
Bevan ER, Jones AM, Hawkey PM (2017). Global epidemiology of CTX-M β-lactamases:Temporal and geographical shifts in genotype. Journal of Antimicrobial Chemotherapy 72(8):2145?2155. |
|
|
Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM (2008a). Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe. Clinical Microbiology and Infection 14:144?153. |
|
|
Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM (2008b). Prevalence and spread of extended?spectrum β?lactamase?producing Enterobacteriaceae in Europe. Clinical Microbiology and infection 14:144?153. |
|
|
CA-SFM/EUCAST (2019). View |
|
|
Duployez C, Loïez C, Cattoen C, Wallet F, Vachée A (2019). In vitro activity of temocillin against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urinary tract infections in France. Médecine et Maladies Infectieuses 49(1):47?53. |
|
|
Habayeb H, Sajin B, Patel K, Grundy C, Al-Dujaili A, Van de Velde S (2015). Amoxicillin plus temocillin as an alternative empiric therapy for the treatment of severe hospital-acquired pneumonia?: Results from a retrospective audit. European Journal of Clinical Microbiology & Infectious Diseases 34:1693?1699. |
|
|
Heard KL, Killington K, Mughal N, Moore LSP, Hughes S (2021). Clinical outcomes of temocillin use for invasive Enterobacterales infections: A single-centre retrospective analysis. JAC-Antimicrobial Resistance 3(1):dlab005. |
|
|
Jena J, Sahoo RK, Debata NK, Subudhi E (2017a). Prevalence of TEM, SHV, and CTX-M genes of extended-spectrum β-lactamase-producing Escherichia coli strains isolated from urinary tract infections in adults. Biotech 7(3):1?7. |
|
|
Jena J, Sahoo RK, Debata NK, Subudhi E (2017b). Prevalence of TEM, SHV, and CTX-M genes of extended-spectrum β-lactamase-producing Escherichia coli strains isolated from urinary tract infections in adults. Biotech 7(3):1?7. |
|
|
Kresken M, Pfeifer Y, Werner G (2021). Comparative in vitro activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin-resistant, carbapenem-susceptible Escherichia coli and Klebsiella pneumoniae. GMS Infectious Diseases 9: Doc08. |
|
|
Kuch A, Zieniuk B, ?abicka D, Van de Velde S, Literacka E, Skoczy?ska A, Hryniewicz W (2020). Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacterales isolated in Poland. European Journal of Clinical Microbiology and Infectious Diseases 39(6):1185?1191. |
|
|
Lacroix M, Zahar JR, Carbonnelle E, Jaureguy F (2021). Pourquoi réserver la témocilline comme alternative en cas d'infection urinaire à BLSE?? Infectious Diseases Now 51(5):S45. |
|
|
Lepeule R, Leflon-Guibout V, Vanjak D, Zahar JR., Lafaurie M, Besson C, Lefort A (2014). Clinical spectrum of urine cultures positive for ESBL-producing Escherichia coli in hospitalized patients and impact on antibiotic use. Médecine et Maladies Infectieuses 44(11?12):530?534. |
|
|
Lupia T, De Benedetto I, Stroffolini G, Di Bella S, Mornese Pinna S, Zerbato V, Rizzello B, Bosio R, Shbaklo N, Corcione S (2022). Temocillin?: Applications in antimicrobial stewardship as a potential carbapenem-sparing antibiotic. Antibiotics 11(4):493. |
|
|
Manoharan A, Premalatha K, Chatterjee S, Mathai D (2011). Correlation of TEM, SHV and CTX-M extended-spectrum beta lactamases among Enterobacteriaceae with their in vitro antimicrobial susceptibility. Indian Journal of Medical Microbiology 29(2):161?164. |
|
|
Manyahi J, Matee MI, Majigo M, Moyo S, Mshana SE, Lyamuya EF (2014). Predominance of multi-drug resistant bacterial pathogens causing surgical site infections in Muhimbili National Hospital, Tanzania. BMC Research Notes 7(1):1?7. |
|
|
Nandagopal B, Sankar S, Sagadevan K, Arumugam H, Jesudason M, Aswathaman K, Nair A (2015). Frequency of extended spectrum β-lactamase producing urinary isolates of Gram-negative bacilli among patients seen in a multispecialty hospital in Vellore district, India. Indian Journal of Medical Microbiology 33(2):282?285. |
|
|
Pitout JD (2010). Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae?: Changing epidemiology and drug treatment choices. Drugs 70:313?333. |
|
|
Rodriguez-Villalobos H, Malaviolle V, Frankard J, Mendonça RD, Nonhoff C, Struelens MJ (2006). In vitro activity of temocillin against extended spectrum β-lactamase-producing Escherichia coli. Journal of Antimicrobial Chemotherapy 57(4):771?774. |
|
|
Rupp ME, Fey PD (2003). Extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae?: Considerations for diagnosis, prevention and drug treatment. Drugs 63:353?365. |
|
|
Sacco MD, Kroeck KG, Kemp MT, Zhang X, Andrews LD, Chen Y (2019). Influence of the α-Methoxy Group on the Reaction of Temocillin with Pseudomonas Aeruginosa PBP3 and CTX-M-14 β-Lactamase. Antimicrobial Agents and Chemotherapy 64(1):10?1128. |
|
|
Saravanan M, Ramachandran B, Barabadi H (2018). The prevalence and drug resistance pattern of extended spectrum β-lactamases (ESBLs) producing Enterobacteriaceae in Africa. Microbial Pathogenesis 114:180?192. |
|
|
Seydou S (2021). Profil épidémiologique et bactériologique des infections urinaires à entérobactéries productrices de bêtalactamases à spectre élargi (E-BLSE) dans le service de néphrologie du CHU du Point G, Bamako, Mali. Revue Africaine et Malgache de Recherche Scientifique/Sciences de la Santé 2(2). |
|
|
Silago V (2021). Beta-lactam antibiotics and extended spectrum beta-lactamases. GSC Advanced Research and Reviews 9(2):15?24. |
|
|
Soubirou J, Rossi B, Couffignal C, Ruppé E, Chau F, Massias L, Lepeule R, Mentre F, Fantin B (2015). Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15. Journal of Antimicrobial Chemotherapy 70(5):1466?1472. |
|
|
Tiemtoré RY, Mètuor-Dabiré A, Zohoncon TM, Bangré YA, Sougue S, Zongo J, Simpore J (2019). First Detection of PE-Type Extended-Spectrum β-lactamases at Saint Camille Hospital Center of Ouagadougou, Burkina Faso. International Journal of Biochemistry, Biophysics and Molecular Biology 4(7). |
|
|
Torres-Sangiao E, Lamas Rodriguez B, Cea Pájaro M, Carracedo Montero R, Parajó Pazos N, García-Riestra C (2022). Direct Urine Resistance Detection Using VITEK 2. Antibiotics (Basel, Switzerland) 11(5):663. |
|
|
Vallee M, Bruyère F, Roblot F, Brureau L (2017). [Temocillin and urinary tract infections]. Progres En Urologie: Journal De l'Association Francaise D'urologie Et De La Societe Francaise D'urologie 27(12):609?617. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
